T66
Conditions
Interventions
Group 1: Patients will be prospectively enrolled who, following cranial radiotherapy for known high-grade astrocytomas/glioblastomas or cerebral metastases, present with imaging findings that cannot b
Sponsors
Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Diagnosis of an astrocytoma grade 3-4, glioblastoma grade 4, or cerebral metastasis of a solid tumor -Previous cranial radiotherapy -Unclear progression (true progression vs. pseudoprogression/radionecrosis) requiring further investigations (cMRI with specialized sequences, stereotactic biopsy, FET-PET) -Decision by an interdisciplinary tumor board recommending FET-PET and tissue sampling for histological clarification of the progression
Exclusion criteria
Exclusion criteria: -Contraindication to undergoing MRI -Contraindication to undergoing FET-PET -Contraindication to undergoing stereotactic biopsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of the CCA in distinguishing between radionecrosis and tumor progression. Measured against the gold standard (histological findings), it should achieve an accuracy of at least 70% (unacceptable outcome) and, ideally, an accuracy of 85% (promising outcome). | — |
Secondary
| Measure | Time frame |
|---|---|
| The accuracy of further examinations (FET-PET, conventional MRI, MR perfusion, MR spectroscopy) in distinguishing between radionecrosis and tumor progression. Measured against the gold standard (histological findings), it should achieve an accuracy of at least 70% (unacceptable outcome) and, ideally, an accuracy of 85% (promising outcome). | — |
Countries
Germany
Contacts
Public ContactRaphael Bodensohn
Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen
Outcome results
None listed